NCT02014909View on ClinicalTrials.gov

A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

May 25, 2017

Study Completion Date

June 5, 2017

Conditions
Advanced Cancer
Interventions
BIOLOGICAL

KTN3379

Single agent KTN3379 or in combination administered until unacceptable toxicity or progressive disease

Trial Locations (5)

19104

University of Pennsylvania Perelman School of Medicine, Philadelphia

37203

Sarah Cannon Research Institute, Nashville

48201

Barbara Ann Karmanos Cancer Institute, Detroit

80218

Sarah Cannon Research Institute, Denver

06511

Yale Cancer Center, New Haven

Sponsors
All Listed Sponsors
lead

Celldex Therapeutics

INDUSTRY